XB-628
- Generic Name
- XB-628
A Study of XB628 in Participants With Recurrent Advanced or Metastatic Solid Tumors
Phase 1
Recruiting
- Conditions
- Solid TumorMetastatic Solid TumorAdvanced Solid TumorImmune Sensitive Tumor
- Interventions
- First Posted Date
- 2025-04-30
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 75
- Registration Number
- NCT06952010
- Locations
- 🇺🇸
Exelixis Clinical Site #1, Hickory, North Carolina, United States
🇺🇸Exelixis Clinical Site #2, San Antonio, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath